Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig + Best Supportive Care vs Placebo + Best Supportive Care in Metastatic Castration-resistant Prostate Cancer
ChiCTR2600117636Phase 3Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pasritamig + Best Supportive Care with Placebo + Best Supportive Care (2 arms). Primary endpoint: Overall Survival (OS). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600117636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117636.